Aernoud Fiolet

300 Chapter 12 ratio, 0.72; 95% confidence interval 0.56 to 0.93, p = 0.012) and very high dose statin use (odds ratio, 0.64; 95% confidence interval 0.43 to 0.92, p = 0.002) were independently associated with intolerance. Univariable and multivariable predictors of gastro-intestinal intolerance In univariable analysis sex, obesity and diabetes were all associated with gastro- intestinal upset ( Figure 3 ). When corrected for other predictors, female sex was independently associated with increased risk for gastro-intestinal upset (odds ratio, 1.45; 95% confidence interval 1.01 to 2.04, p = 0.036). Obesity showed an inverse relation with the occurrence of gastro-intestinal upset (odds ratio, 0.65; 95% confidence interval 0.48 to 0.89, p = 0.007). Other demographic factors, medical history or concomitant drugs did not show any significant associationwith the occurrence of gastro-intestinal upset after correction for all other variables. Univariable and multivariable predictors of myalgia Although univariable analyses showed an increase in the odds for myalgia in participants with a history of atrial fibrillation, this association appeared to be explained by other factors as no such relation remained after correcting with a multivariable model (Figure 4) . Participants using ezetimibe numerically reported myalgia less often as compared to those not using ezetimibe (0.8% versus 1.7%), although this association did not reach statistical significance. Figure 3: Univariable and multivariable associations with intolerance due to gastro-intestinal upset. Crude OR Adjusted OR Predictors OR 95% confidence interval P Value OR 95% confidence interval P Value Forrest plot Female sex 1.46 (1.03 to 2.05) 0.029 1.45 (1.01 to 2.04) 0.036 Age above 70 years 1.31 (0.97 to 1.76) 0.078 1.20 (0.87 to 1.65) 0.258 Non caucasian race 1.39 (0.62 to 2.72) 0.374 1.50 (0.66 to 2.96) 0.283 Active smoker 1.02 (0.67 to 1.48) 0.934 1.04 (0.68 to 1.53) 0.866 Obesity 0.62 (0.46 to 0.85) 0.002 0.65 (0.48 to 0.89) 0.007 Hypertension 1.06 (0.80 to 1.42) 0.670 1.10 (0.81 to 1.49) 0.556 Diabetes 0.63 (0.40 to 0.95) 0.036 0.73 (0.43 to 1.16) 0.206 Diabetes on insulin 0.46 (0.16 to 1.02) 0.091 0.60 (0.20 to 1.52) 0.319 eGFR < 60 ml/min/1.73m2 1.56 (0.99 to 2.37) 0.044 1.48 (0.93 to 2.28) 0.085 History of myocardial infarction 0.97 (0.72 to 1.30) 0.822 0.97 (0.72 to 1.32) 0.856 History of LVEF < 50% 1.32 (0.85 to 1.99) 0.195 1.48 (0.93 to 2.27) 0.087 History of atrial fibrillation 1.09 (0.71 to 1.63) 0.672 1.23 (0.62 to 2.44) 0.551 Anticoagulant use 1.02 (0.67 to 1.51) 0.913 0.79 (0.39 to 1.52) 0.492 Beta-blocker use 1.00 (0.74 to 1.36) 0.992 1.00 (0.73 to 1.37) 0.979 Calcium-channel blocker 1.05 (0.74 to 1.47) 0.778 1.08 (0.75 to 1.52) 0.688 Renin angiotensin inhibitor use 0.87 (0.64 to 1.18) 0.366 0.88 (0.64 to 1.22) 0.440 High-dose statin use 0.98 (0.73 to 1.30) 0.862 1.03 (0.75 to 1.42) 0.847 Very high-dose statin use 0.87 (0.58 to 1.27) 0.485 0.89 (0.57 to 1.35) 0.579 Ezetimibe use 0.86 (0.6 to 1.21) 0.396 0.88 (0.61 to 1.24) 0.483 Figure 3 : Univariable and multivariable associations with intolerance due to gastro-intestinal upset to low-dose colchicine. All predictors of the unvariable model were entered in the multivariable model. Abbrevations: eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; OR, odds ratio Figure 3: Univariable and multivariable associations with intolerance due to gastro-intestinal upset to low-dose colchicine. All predictors of the unvariable model were entered in the multivariable model. Abbrevations: eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; OR, odds rati